
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Study on TLC590 for Managing Postsurgical Pain Following Bunionectomy
Details : Ropivacaine HCl is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2025
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy
Details : Results showed that TLC599 (Dexamethasone Sodium Phosphate), a proprietary BioSeizer, demonstrated statistically significantly greater reduction in WOMAC pain and function as well as VAS scores compared to placebo through 24 weeks.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
March 07, 2022
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amphotericin B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Partnership
TLC and Strides partner to launch Liposomal Amphotericin B in India
Details : The partnership aims to support the TLC for the launch and commercialization of their lead product AmphoTLC (amphotericin B) in India. It will be indicated for the COVID-19-associated mucormycosis cases.
Product Name : AmphoTLC
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 19, 2021
Lead Product(s) : Amphotericin B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Partnership

Contact Us!